Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine

Vaccine

Volumn 33, Issue 28, 2015, Pages 3248-3255

  Pearson, Frances E ^a   O'Mahony, Conor ^b   Moore, Anne C ^c   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Adenovirus; Challenge; Malaria; Microneedle; Skin vaccination; T cell

Indexed keywords

ADENOVIRUS VECTOR; CHIMPANZEE ADENOVIRUS SEROTYPE 63 VECTOR; MALARIA VACCINE; PLASMODIUM BERGHEI CIRCUMSPOROZOITE PROTEIN MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 EPITOPE PB9 THROMBOSPONDIN RELATED ADHESIVE PROTEIN FUSION PROTEIN; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG; LIVE VACCINE; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; SILICON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HETEROLOGOUS IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; INFECTION PREVENTION; LYMPH NODE; MALARIA; MICRONEEDLE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SILICON MICRONEEDLE ARRAY; SINGLE DRUG DOSE; SKIN DRAINING LYMPH NODE; SPOROZOITE; SYRINGE NEEDLE; TRANSGENE; VACCINATION; ANIMAL; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; NEEDLE; PLASMODIUM FALCIPARUM; PROCEDURES; SIMIAN VIRUS;

ADENOVIRUSES, SIMIAN; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; INJECTIONS, INTRADERMAL; MALARIA; MALARIA VACCINES; MICE; NEEDLES; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; SILICON; SPOROZOITES; TRANSGENES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84930573102     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.039     Document Type: Article

References (27)

1. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999, 77(10):789-800.
2. Hill A.V. Vaccines against malaria. Philos Trans R Soc Lond, B: Biol Sci 2011, 366(1579):2806-2814.
3. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(1):62-73.
4. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccines 2010, 6(1):78-83.
5. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78(1):145-153.
6. Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier C.S., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010, 29(2):256-265.
7. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(5):772-781.
8. Ogwang C., Afolabi M., Kimani D., Jagne Y.J., Sheehy S.H., Bliss C.M., et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE 2013, 8(3):e57726.
9. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
10. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7(2):e31208.
11. Ormerod L.P., Palmer C. Tuberculin reactivity after neonatal percutaneous BCG immunisation. Arch Dis Child 1993, 69(1):155.
12. Ormerod L.P., Garnett J.M. Tuberculin response after neonatal BCG vaccination. Arch Dis Child 1988, 63(12):1491-1492.
13. Carey J.B., Pearson F.E., Vrdoljak A., McGrath M.G., Crean A.M., Walsh P.T., et al. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS ONE 2011, 6(7):e22442.
14. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997, 15(12):1280-1284.
15. Pearson F.E., McNeilly C.L., Crichton M.L., Primiero C.A., Yukiko S.R., Fernando G.J., et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS ONE 2013, 8(7):e67888.
16. Bachy V., Hervouet C., Becker P.D., Chorro L., Carlin L.M., Herath S., et al. Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci USA 2013, 110(8):3041-3046.
17. Wilke N., Mulcahy A., Ye S.-R., Morrissey A. Process optimization and characterization of silicon microneedles fabricated by wet etch technology. Microelectr J 2005, 36:650-656.
18. Reyes-Sandoval A., Pearson F.E., Todryk S., Ewer K. Potency assays for novel T-cell-inducing vaccines against malaria. Curr Opin Mol Ther 2009, 11(1):72-80.
19. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008, 38(3):732-741.
20. Moore A.C., Gallimore A., Draper S.J., Watkins K.R., Gilbert S.C., Hill A.V. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol 2005, 175(11):7264-7273.
21. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011, 187(3):1347-1357.
22. Vrdoljak A., McGrath M.G., Carey J.B., Draper S.J., Hill A.V., O'Mahony C., et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 2012, 159(1):34-42.
23. Carey J.B., Vrdoljak A., O'Mahony C., Hill A.V., Draper S.J., Moore A.C. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Rep 2014, 4:6154.
24. Bal S.M., Kruithof A.C., Zwier R., Dietz E., Bouwstra J.A., Lademann J., et al. Influence of microneedle shape on the transport of a fluorescent dye into human skin in vivo. J Control Release 2010, 147(2):218-224.
25. Puri N., Weyand E.H., Abdel-Rahman S.M., Sinko P.J. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems. Vaccine 2000, 18(23):2600-2612.
26. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7(8):1201-1214.
27. Dicks M.D., Guzman E., Spencer A.J., Gilbert S.C., Charleston B., Hill A.V., et al. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine 2015, 33(9):1121-1128.